Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AgomAb Therapeutics NV - ADRs representing one common share.
(NQ:
AGMB
)
8.360
+0.030 (+0.36%)
Delayed Quote
Updated: 3:28 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AgomAb Therapeutics NV - ADRs representing one common share.
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
October 13, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
October 08, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
October 01, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
September 14, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
September 11, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab to Participate in Upcoming Investor Conferences
September 03, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
August 10, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
August 06, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
June 23, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Announces Results of Annual General Meeting
May 27, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab to Participate in Upcoming Conferences
May 14, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
April 23, 2026
From
AgomAb Therapeutics NV
Via
GlobeNewswire
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026
From
AgomAb Therapeutics N.V.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
